EE9700133A - Meetod imetaja reproduktiivtrakti rakkude karakteristikute muutmiseks, selleks kasutatav kompositsioon, selle valmistamise meetod ja kasutamine - Google Patents

Meetod imetaja reproduktiivtrakti rakkude karakteristikute muutmiseks, selleks kasutatav kompositsioon, selle valmistamise meetod ja kasutamine

Info

Publication number: EE9700133A
Authority: EE; Estonia
Prior art keywords: modifying; preparation; composition used; reproductive cells; mammalian reproductive
Prior art date: 1994-12-24

Application number

EE9700133A

Other languages

English (en)

Other versions

EE03955B1 (et

Inventor

Stephen Charnock-Jones David

Kevin Smith Stephen

Mark Sharkey Andrew

Brian Heap Robert

Original Assignee

Cambridge University Technical Services Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-24

Filing date

1995-12-21

Publication date

1997-12-15

1994-12-24 Priority claimed from GBGB9426380.3A external-priority patent/GB9426380D0/en

1995-12-21 Application filed by Cambridge University Technical Services Limited filed Critical Cambridge University Technical Services Limited

1997-12-15 Publication of EE9700133A publication Critical patent/EE9700133A/et

2003-02-17 Publication of EE03955B1 publication Critical patent/EE03955B1/et

Links

210000005132 reproductive cell Anatomy 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 abstract 2
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
210000005000 reproductive tract Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Gynecology & Obstetrics (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)

EE9700133A 1994-12-24 1995-12-21 Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks EE03955B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9426380.3A GB9426380D0 (en)	1994-12-24	1994-12-24	Regulation of endometrial function by in vivo gene transfer
GBGB9520879.9A GB9520879D0 (en)	1994-12-24	1995-10-12	Improvements in or relating to endometrial function
PCT/GB1995/003008 WO1996020013A1 (en)	1994-12-24	1995-12-21	Improvements in or relating to endometrial function

Publications (2)

Publication Number	Publication Date
EE9700133A true EE9700133A (et)	1997-12-15
EE03955B1 EE03955B1 (et)	2003-02-17

Family

ID=26306279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9700133A EE03955B1 (et)	1994-12-24	1995-12-21	Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks

Country Status (23)

Country	Link
US (2)	US6472374B1 (et)
EP (1)	EP0799058B1 (et)
JP (2)	JPH10511548A (et)
KR (1)	KR20050052548A (et)
CN (1)	CN1241646C (et)
AT (1)	ATE234637T1 (et)
AU (1)	AU712278B2 (et)
BG (1)	BG63332B1 (et)
BR (1)	BR9510408A (et)
CA (1)	CA2208446A1 (et)
CZ (1)	CZ293770B6 (et)
DE (1)	DE69530001T2 (et)
DK (1)	DK0799058T3 (et)
EE (1)	EE03955B1 (et)
ES (1)	ES2323909T3 (et)
HU (1)	HU221204B1 (et)
MX (1)	MX9704765A (et)
NO (1)	NO320436B1 (et)
NZ (1)	NZ297537A (et)
PL (1)	PL192784B1 (et)
PT (1)	PT799058E (et)
SK (1)	SK284119B6 (et)
WO (1)	WO1996020013A1 (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002541822A (ja)	1999-04-14	2002-12-10	エムユーエスシーファンデーションフォーリサーチディベロップメント	組織特異的および病原体特異的毒性物質ならびにリボザイム
US6777639B2 (en) *	2002-06-12	2004-08-17	Nanotechnologies, Inc.	Radial pulsed arc discharge gun for synthesizing nanopowders
CA2491034A1 (en)	2002-06-26	2004-01-08	The Penn State Research Foundation	Methods and materials for treating human papillomavirus infections
US7012214B2 (en) *	2003-09-24	2006-03-14	Nanotechnologies, Inc.	Nanopowder synthesis using pulsed arc discharge and applied magnetic field
EP1687022A4 (en)	2003-11-12	2008-02-13	Medical Res Council	RENTA: HIV IMMUNOGENIC AND ITS APPLICATIONS
AU2007256717B2 (en)	2006-06-02	2013-06-20	International Aids Vaccine Initiative	HIV-1 Clade A consensus sequences, antigens, and transgenes
US20080050814A1 (en) *	2006-06-05	2008-02-28	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of fetal placental cells
US20080064098A1 (en) *	2006-06-05	2008-03-13	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of maternal placental cells
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
JP6407714B2 (ja)	2011-04-25	2018-10-17	アドヴァンスドバイオサイエンスラボラトリーズインコーポレイテッド	短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
EP2586461A1 (en)	2011-10-27	2013-05-01	Christopher L. Parks	Viral particles derived from an enveloped virus
WO2013093629A2 (en)	2011-12-20	2013-06-27	Netherlands Cancer Institute	Modular vaccines, methods and compositions related thereto
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
US9347065B2 (en)	2012-03-29	2016-05-24	International Aids Vaccine Initiative	Methods to improve vector expression and genetic stability
EP2679596B1 (en)	2012-06-27	2017-04-12	International Aids Vaccine Initiative	HIV-1 env glycoprotein variant
WO2014040025A2 (en)	2012-09-10	2014-03-13	International Aids Vaccine Initiative	Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
US20150065381A1 (en)	2013-09-05	2015-03-05	International Aids Vaccine Initiative	Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
US10093720B2 (en)	2014-06-11	2018-10-09	International Aids Vaccine Initiative	Broadly neutralizing antibody and uses thereof
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en)	2015-10-02	2018-03-27	International Aids Vaccine Initiative	Replication-competent VSV-HIV Env vaccines
KR101802090B1 (ko)	2016-09-26	2017-11-27	서울대학교산학협력단	탈락막 자궁내막 세포를 포함하는 자궁내막 손상의 치료용 조성물
CN113924114A (zh)	2019-05-22	2022-01-11	吉利德科学公司	Tlr7调节化合物和hiv疫苗的组合
AU2020384323A1 (en)	2019-11-14	2022-06-02	Aelix Therapeutics, S.L.	Dosage regimens for vaccines
EP4106809A1 (en)	2020-02-21	2022-12-28	International AIDS Vaccine Initiative, Inc.	Vaccine compositions for preventing coronavirus disease
CN112458161A (zh) *	2020-11-12	2021-03-09	深圳市锦欣医疗科技创新中心有限公司	一组子宫内膜容受性生物标志物、试剂盒及判断子宫内膜容受性的方法
KR20220083029A (ko) *	2020-12-11	2022-06-20	주식회사 커스토젠	자궁내막 비후용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5858784A (en) *	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994005782A1 (en) *	1992-09-10	1994-03-17	Trustees Of Tufts College	In vivo production of transgenic organ by introducing the transgene via lumen
GB9410534D0 (en) *	1994-05-26	1994-07-13	Lynxvale Ltd	Improvements in or relating to growth factor inhibitors

1995
- 1995-12-21 KR KR1020057008617A patent/KR20050052548A/ko not_active Ceased
- 1995-12-21 NZ NZ297537A patent/NZ297537A/xx unknown
- 1995-12-21 CN CNB951974637A patent/CN1241646C/zh not_active Expired - Fee Related
- 1995-12-21 ES ES95941229T patent/ES2323909T3/es not_active Expired - Lifetime
- 1995-12-21 EE EE9700133A patent/EE03955B1/et not_active IP Right Cessation
- 1995-12-21 DK DK95941229T patent/DK0799058T3/da active
- 1995-12-21 DE DE69530001T patent/DE69530001T2/de not_active Expired - Fee Related
- 1995-12-21 CA CA002208446A patent/CA2208446A1/en not_active Abandoned
- 1995-12-21 SK SK801-97A patent/SK284119B6/sk unknown
- 1995-12-21 EP EP95941229A patent/EP0799058B1/en not_active Expired - Lifetime
- 1995-12-21 BR BR9510408A patent/BR9510408A/pt not_active Application Discontinuation
- 1995-12-21 MX MX9704765A patent/MX9704765A/es not_active IP Right Cessation
- 1995-12-21 US US08/860,047 patent/US6472374B1/en not_active Expired - Fee Related
- 1995-12-21 AT AT95941229T patent/ATE234637T1/de not_active IP Right Cessation
- 1995-12-21 PT PT95941229T patent/PT799058E/pt unknown
- 1995-12-21 WO PCT/GB1995/003008 patent/WO1996020013A1/en not_active Ceased
- 1995-12-21 JP JP8520293A patent/JPH10511548A/ja active Pending
- 1995-12-21 AU AU42707/96A patent/AU712278B2/en not_active Ceased
- 1995-12-21 PL PL324088A patent/PL192784B1/pl not_active IP Right Cessation
- 1995-12-21 CZ CZ19971917A patent/CZ293770B6/cs not_active IP Right Cessation
- 1995-12-21 HU HU9702205A patent/HU221204B1/hu not_active IP Right Cessation
1997
- 1997-06-23 NO NO19972935A patent/NO320436B1/no unknown
- 1997-07-01 BG BG101714A patent/BG63332B1/bg unknown
2002
- 2002-09-24 US US10/252,404 patent/US20030186907A1/en not_active Abandoned
2006
- 2006-01-13 JP JP2006006212A patent/JP2006124402A/ja active Pending

Also Published As

Publication number	Publication date
KR20050052548A (ko)	2005-06-02
DE69530001T2 (de)	2004-06-03
BG101714A (en)	1998-03-31
PL192784B1 (pl)	2006-12-29
CZ191797A3 (cs)	1998-06-17
AU4270796A (en)	1996-07-19
US20030186907A1 (en)	2003-10-02
NO972935D0 (no)	1997-06-23
DE69530001D1 (de)	2003-04-24
ATE234637T1 (de)	2003-04-15
AU712278B2 (en)	1999-11-04
US6472374B1 (en)	2002-10-29
PL324088A1 (en)	1998-05-11
EP0799058B1 (en)	2003-03-19
CZ293770B6 (cs)	2004-07-14
MX9704765A (es)	1998-02-28
BR9510408A (pt)	1998-11-10
PT799058E (pt)	2003-11-28
ES2323909T3 (es)	2009-07-27
SK284119B6 (sk)	2004-09-08
EP0799058A1 (en)	1997-10-08
JP2006124402A (ja)	2006-05-18
WO1996020013A1 (en)	1996-07-04
CN1241646C (zh)	2006-02-15
NO972935L (no)	1997-08-22
EE03955B1 (et)	2003-02-17
SK80197A3 (en)	1998-04-08
CN1174508A (zh)	1998-02-25
JPH10511548A (ja)	1998-11-10
DK0799058T3 (da)	2003-11-24
NO320436B1 (no)	2005-12-05
NZ297537A (en)	2000-04-28
HUT77338A (hu)	1998-03-30
BG63332B1 (bg)	2001-10-31
CA2208446A1 (en)	1996-07-04
HU221204B1 (en)	2002-08-28

Legal Events

Date	Code	Title	Description
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2009-08-17	MM4A	Lapsed by not paying the annual fees	Effective date: 20081221

Publication	Publication Date	Title
EE03955B1 (et)	2003-02-17	Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
BR9507140A (pt)	1997-09-30	Proteina dna vetor célula capaz de expressar uma proteina kit e processo de teste preparado de luciferase e uso de uma luciferase
ATE251805T1 (de)	2003-10-15	Verfahren zur herstellung von polybenzimidazol- pasten und -gelen zur verwendung in brennstoffzellen
ES2098531T3 (es)	1997-05-01	Composiciones humectables de hidrogel que contienen silicona y metodos.
DE69334239D1 (de)	2008-09-25	Positives aktives Material, Verfahren zur Herstellung und dieses verwendende Sekundärbatterie
DE3768764D1 (de)	1991-04-25	Phosphorsaeure-brennstoffzellenstapel mit hohem druck- und niedriegem waermebetrag.
CA2058930A1 (en)	1990-12-15	Media for cell growth and method for making them
AU4295496A (en)	1996-07-24	Production of a contractile smooth muscle
DE68901782D1 (de)	1992-07-23	Brennstoffzelle, elektrode fuer die zelle und verfahren zur herstellung.
DE3583170D1 (de)	1991-07-18	Elektrode fuer brennstoffzelle, verfahren zu ihrer herstellung und diese elektrode verwendende brennstoffzelle.
DE69007361D1 (de)	1994-04-21	Festoxidbrennstoffzelle und Verfahren zu ihrer Herstellung.
FI874957L (fi)	1988-05-12	Läpikuultavia koostumuksia, joiden sameus on vähäinen, ja menetelmä niiden valmistamiseksi
DE60140526D1 (de)	2009-12-31	Herstellung von tcr gamma delta t-zellen
DE3888887D1 (de)	1994-05-11	Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
ATE196165T1 (de)	2000-09-15	Methoden zur herstellung von protein c
FI862943A7 (fi)	1987-01-17	Aryylietanolihydroksyyliamiinit, niiden valmistusmenetelmä ja niiden käyttö suorituskyvyn parantamiseen.
DE69012168D1 (de)	1994-10-13	Nichtwässerige elektrochemische Zelle und Verfahren zu ihrer Herstellung.
AR224900A1 (es)	1982-01-29	Un conjunto de ensayo u.v.cinetico para la determinacion simultanea de transaminasa glutamica oxalacetica(got)y transaminasa glutamica piruvica(gpt)en una sola muestra de suero o plasma
WO1998021326A3 (en)	1998-10-08	Methods for producing the anaphase promoting complex
DE58908775D1 (de)	1995-01-26	2-Halogensubstituierte N-Indolylethyl-sulfonsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln.
BR8904681A (pt)	1990-05-01	Uma linha de celulas de hibridoma,mutantes,anticorpos,processos para a preparacao de uma linha de celulas e para a preparacao de anticorpos e processo e agente para comprovacao imunologica de atrazina
KR840008644A (ko)	1984-12-17	원예재배용 클로레라 비료의 제조방법
MX155768A (es)	1988-04-25	Composicion colorante pulverulenta,estable en dispersion y procedimiento para su fabricacion
PT1007498E (pt)	2002-07-31	Processo para o fabrico de 2-halogenoindano-1-onas
CHEN	1978	Evolution and Taxonomy